Assessment of clinical efficacy and safety in capecitabine plus intermittent oxaliplatin (intermittent CapeOx) together with Bevacizumab as the first-line therapy for patients with advanced colorectal cancer; multicenter phase II trial

Trial Profile

Assessment of clinical efficacy and safety in capecitabine plus intermittent oxaliplatin (intermittent CapeOx) together with Bevacizumab as the first-line therapy for patients with advanced colorectal cancer; multicenter phase II trial

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms VOICE
  • Most Recent Events

    • 20 Jan 2018 Status changed from recruiting to completed, according to the results presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Primary endpoint (Progression free survival) has been met. according to the results presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Final results presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top